Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine
In anticipation of future combination vaccines, a recombinant class 3 porin (rPorB) of group B meningococci was evaluated as an alternative carrier protein for a Haemophilus influenzae type b (Hib) polyribosylribotol phosphate (PRP) conjugate vaccine. The use of rPorB may avoid undesirable immunolog...
Gespeichert in:
| Veröffentlicht in: | Vaccine 1998-11, Vol.16 (19), p.1842-1849 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1849 |
|---|---|
| container_issue | 19 |
| container_start_page | 1842 |
| container_title | Vaccine |
| container_volume | 16 |
| creator | Fusco, Peter C. Michon, Francis Laude-Sharp, Maryline Minetti, Conceição A.S.A. Huang, Chun-Hsien Heron, Iver Blake, M.S. |
| description | In anticipation of future combination vaccines, a recombinant class 3 porin (rPorB) of group B meningococci was evaluated as an alternative carrier protein for a
Haemophilus influenzae type b (Hib) polyribosylribotol phosphate (PRP) conjugate vaccine. The use of rPorB may avoid undesirable immunologic interactions among vaccine components, including epitopic suppression from conventional carriers (e.g. tetanus toxoid [TT]), as well as provide desirable immunomodulatory effects. Rats were found to be more reliable and consistent than mice or guinea pigs for studying antibody responses to the Hib conjugates. Different Hib conjugates, Hib-TT and Hib-rPorB, consisting of PRP conjugated by reductive amination to TT or rPorB, were compared in rats. Commercially available, licensed vaccines, HbOC (HibTITER
®) and PRP-T (OmniHib
®), were used as reference controls. Maximum geometric mean ELISA IgG titers were obtained in rats after only two doses, showing booster effects for all. However, Hib-rPorB immunization consistently resulted in responses that were 1–2 orders of magnitude greater than those for the other conjugates, including the licensed control vaccines. A maximum 4600-fold rise was observed for Hib-rPorB after two doses, and, unlike the other conjugates, a 100% response rate was always achieved without adjuvant. These results warrant further investigation of Hib-rPorB in combination with DTaP. |
| doi_str_mv | 10.1016/S0264-410X(98)00174-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70008968</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X98001741</els_id><sourcerecordid>70008968</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-d6da47bc003a1ebd491863957c91b6c12a9fc818a76ec459791dea9630b234783</originalsourceid><addsrcrecordid>eNqFkcFq3DAQhkVpSTdJHyGgQynpwY1k2bJ0KklomkKggSTQm5DH462CLbmSvZC-Qd-62uySHnsS0nwzkr6fkBPOPnHG5dkdK2VVVJz9ONXqI2O8qQr-iqy4akRR1ly9JqsX5C05TOmRMVYLrg_IgW50LTRbkT-3EWFw3oEdaJqXzmGiwVNL83kYW-etn-k6hmWiF3RE7_w6QIAtPoXoMpkyDDZGh5H2IeadDxsc6LXFMUw_3bAk6nw_LOh_W6Tz04S0pRD847K2M9KNBXAej8mb3g4J3-3XI_Jw9eX-8rq4-f712-X5TQFC6bnoZGerpgXGhOXYdpXmSgpdN6B5K4GXVveguLKNRKjq_FHeodVSsLYUVaPEEfmwmzvF8GvBNJvRJcBhsB7DkkyTLSktt2C9AyGGlCL2ZoputPHJcGa2EZjnCMzWr9HKPEdgeO472V-wtCN2L11757n-fl-3KWvso_Xg0r_hUnJRVhn7vMMwy9hkuSaBQw_YuRzNbLrg_vOQv3EfpOo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70008968</pqid></control><display><type>article</type><title>Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Fusco, Peter C. ; Michon, Francis ; Laude-Sharp, Maryline ; Minetti, Conceição A.S.A. ; Huang, Chun-Hsien ; Heron, Iver ; Blake, M.S.</creator><creatorcontrib>Fusco, Peter C. ; Michon, Francis ; Laude-Sharp, Maryline ; Minetti, Conceição A.S.A. ; Huang, Chun-Hsien ; Heron, Iver ; Blake, M.S.</creatorcontrib><description>In anticipation of future combination vaccines, a recombinant class 3 porin (rPorB) of group B meningococci was evaluated as an alternative carrier protein for a
Haemophilus influenzae type b (Hib) polyribosylribotol phosphate (PRP) conjugate vaccine. The use of rPorB may avoid undesirable immunologic interactions among vaccine components, including epitopic suppression from conventional carriers (e.g. tetanus toxoid [TT]), as well as provide desirable immunomodulatory effects. Rats were found to be more reliable and consistent than mice or guinea pigs for studying antibody responses to the Hib conjugates. Different Hib conjugates, Hib-TT and Hib-rPorB, consisting of PRP conjugated by reductive amination to TT or rPorB, were compared in rats. Commercially available, licensed vaccines, HbOC (HibTITER
®) and PRP-T (OmniHib
®), were used as reference controls. Maximum geometric mean ELISA IgG titers were obtained in rats after only two doses, showing booster effects for all. However, Hib-rPorB immunization consistently resulted in responses that were 1–2 orders of magnitude greater than those for the other conjugates, including the licensed control vaccines. A maximum 4600-fold rise was observed for Hib-rPorB after two doses, and, unlike the other conjugates, a 100% response rate was always achieved without adjuvant. These results warrant further investigation of Hib-rPorB in combination with DTaP.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(98)00174-1</identifier><identifier>PMID: 9795390</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antibodies, Viral - biosynthesis ; Antibodies, Viral - blood ; Bacterial Capsules ; Bacterial Outer Membrane Proteins - immunology ; Bacteriology ; Biological and medical sciences ; conjugate ; Enzyme-Linked Immunosorbent Assay ; Female ; Fundamental and applied biological sciences. Psychology ; Haemophilus influenzae ; Haemophilus Vaccines - immunology ; Haemophilus Vaccines - pharmacology ; Immunoglobulin G - biosynthesis ; Immunoglobulin G - blood ; Mice ; Mice, Inbred Strains ; Microbiology ; Neisseria meningitidis - immunology ; Polysaccharides, Bacterial - immunology ; porin ; Porins ; Rats ; Rats, Sprague-Dawley ; Recombinant Proteins - biosynthesis ; Recombinant Proteins - genetics ; Recombinant Proteins - immunology ; Tetanus Toxoid - pharmacology ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Conjugate - pharmacology</subject><ispartof>Vaccine, 1998-11, Vol.16 (19), p.1842-1849</ispartof><rights>1998</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-d6da47bc003a1ebd491863957c91b6c12a9fc818a76ec459791dea9630b234783</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0264-410X(98)00174-1$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>310,311,315,781,785,790,791,3551,23935,23936,25145,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1661324$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9795390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fusco, Peter C.</creatorcontrib><creatorcontrib>Michon, Francis</creatorcontrib><creatorcontrib>Laude-Sharp, Maryline</creatorcontrib><creatorcontrib>Minetti, Conceição A.S.A.</creatorcontrib><creatorcontrib>Huang, Chun-Hsien</creatorcontrib><creatorcontrib>Heron, Iver</creatorcontrib><creatorcontrib>Blake, M.S.</creatorcontrib><title>Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>In anticipation of future combination vaccines, a recombinant class 3 porin (rPorB) of group B meningococci was evaluated as an alternative carrier protein for a
Haemophilus influenzae type b (Hib) polyribosylribotol phosphate (PRP) conjugate vaccine. The use of rPorB may avoid undesirable immunologic interactions among vaccine components, including epitopic suppression from conventional carriers (e.g. tetanus toxoid [TT]), as well as provide desirable immunomodulatory effects. Rats were found to be more reliable and consistent than mice or guinea pigs for studying antibody responses to the Hib conjugates. Different Hib conjugates, Hib-TT and Hib-rPorB, consisting of PRP conjugated by reductive amination to TT or rPorB, were compared in rats. Commercially available, licensed vaccines, HbOC (HibTITER
®) and PRP-T (OmniHib
®), were used as reference controls. Maximum geometric mean ELISA IgG titers were obtained in rats after only two doses, showing booster effects for all. However, Hib-rPorB immunization consistently resulted in responses that were 1–2 orders of magnitude greater than those for the other conjugates, including the licensed control vaccines. A maximum 4600-fold rise was observed for Hib-rPorB after two doses, and, unlike the other conjugates, a 100% response rate was always achieved without adjuvant. These results warrant further investigation of Hib-rPorB in combination with DTaP.</description><subject>Animals</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Antibodies, Viral - blood</subject><subject>Bacterial Capsules</subject><subject>Bacterial Outer Membrane Proteins - immunology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>conjugate</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Haemophilus influenzae</subject><subject>Haemophilus Vaccines - immunology</subject><subject>Haemophilus Vaccines - pharmacology</subject><subject>Immunoglobulin G - biosynthesis</subject><subject>Immunoglobulin G - blood</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Microbiology</subject><subject>Neisseria meningitidis - immunology</subject><subject>Polysaccharides, Bacterial - immunology</subject><subject>porin</subject><subject>Porins</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Recombinant Proteins - biosynthesis</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - immunology</subject><subject>Tetanus Toxoid - pharmacology</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Conjugate - pharmacology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFq3DAQhkVpSTdJHyGgQynpwY1k2bJ0KklomkKggSTQm5DH462CLbmSvZC-Qd-62uySHnsS0nwzkr6fkBPOPnHG5dkdK2VVVJz9ONXqI2O8qQr-iqy4akRR1ly9JqsX5C05TOmRMVYLrg_IgW50LTRbkT-3EWFw3oEdaJqXzmGiwVNL83kYW-etn-k6hmWiF3RE7_w6QIAtPoXoMpkyDDZGh5H2IeadDxsc6LXFMUw_3bAk6nw_LOh_W6Tz04S0pRD847K2M9KNBXAej8mb3g4J3-3XI_Jw9eX-8rq4-f712-X5TQFC6bnoZGerpgXGhOXYdpXmSgpdN6B5K4GXVveguLKNRKjq_FHeodVSsLYUVaPEEfmwmzvF8GvBNJvRJcBhsB7DkkyTLSktt2C9AyGGlCL2ZoputPHJcGa2EZjnCMzWr9HKPEdgeO472V-wtCN2L11757n-fl-3KWvso_Xg0r_hUnJRVhn7vMMwy9hkuSaBQw_YuRzNbLrg_vOQv3EfpOo</recordid><startdate>19981101</startdate><enddate>19981101</enddate><creator>Fusco, Peter C.</creator><creator>Michon, Francis</creator><creator>Laude-Sharp, Maryline</creator><creator>Minetti, Conceição A.S.A.</creator><creator>Huang, Chun-Hsien</creator><creator>Heron, Iver</creator><creator>Blake, M.S.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981101</creationdate><title>Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine</title><author>Fusco, Peter C. ; Michon, Francis ; Laude-Sharp, Maryline ; Minetti, Conceição A.S.A. ; Huang, Chun-Hsien ; Heron, Iver ; Blake, M.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-d6da47bc003a1ebd491863957c91b6c12a9fc818a76ec459791dea9630b234783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Antibodies, Viral - blood</topic><topic>Bacterial Capsules</topic><topic>Bacterial Outer Membrane Proteins - immunology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>conjugate</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Haemophilus influenzae</topic><topic>Haemophilus Vaccines - immunology</topic><topic>Haemophilus Vaccines - pharmacology</topic><topic>Immunoglobulin G - biosynthesis</topic><topic>Immunoglobulin G - blood</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Microbiology</topic><topic>Neisseria meningitidis - immunology</topic><topic>Polysaccharides, Bacterial - immunology</topic><topic>porin</topic><topic>Porins</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Recombinant Proteins - biosynthesis</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - immunology</topic><topic>Tetanus Toxoid - pharmacology</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Conjugate - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fusco, Peter C.</creatorcontrib><creatorcontrib>Michon, Francis</creatorcontrib><creatorcontrib>Laude-Sharp, Maryline</creatorcontrib><creatorcontrib>Minetti, Conceição A.S.A.</creatorcontrib><creatorcontrib>Huang, Chun-Hsien</creatorcontrib><creatorcontrib>Heron, Iver</creatorcontrib><creatorcontrib>Blake, M.S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fusco, Peter C.</au><au>Michon, Francis</au><au>Laude-Sharp, Maryline</au><au>Minetti, Conceição A.S.A.</au><au>Huang, Chun-Hsien</au><au>Heron, Iver</au><au>Blake, M.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>1998-11-01</date><risdate>1998</risdate><volume>16</volume><issue>19</issue><spage>1842</spage><epage>1849</epage><pages>1842-1849</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>In anticipation of future combination vaccines, a recombinant class 3 porin (rPorB) of group B meningococci was evaluated as an alternative carrier protein for a
Haemophilus influenzae type b (Hib) polyribosylribotol phosphate (PRP) conjugate vaccine. The use of rPorB may avoid undesirable immunologic interactions among vaccine components, including epitopic suppression from conventional carriers (e.g. tetanus toxoid [TT]), as well as provide desirable immunomodulatory effects. Rats were found to be more reliable and consistent than mice or guinea pigs for studying antibody responses to the Hib conjugates. Different Hib conjugates, Hib-TT and Hib-rPorB, consisting of PRP conjugated by reductive amination to TT or rPorB, were compared in rats. Commercially available, licensed vaccines, HbOC (HibTITER
®) and PRP-T (OmniHib
®), were used as reference controls. Maximum geometric mean ELISA IgG titers were obtained in rats after only two doses, showing booster effects for all. However, Hib-rPorB immunization consistently resulted in responses that were 1–2 orders of magnitude greater than those for the other conjugates, including the licensed control vaccines. A maximum 4600-fold rise was observed for Hib-rPorB after two doses, and, unlike the other conjugates, a 100% response rate was always achieved without adjuvant. These results warrant further investigation of Hib-rPorB in combination with DTaP.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>9795390</pmid><doi>10.1016/S0264-410X(98)00174-1</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 1998-11, Vol.16 (19), p.1842-1849 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70008968 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Antibodies, Viral - biosynthesis Antibodies, Viral - blood Bacterial Capsules Bacterial Outer Membrane Proteins - immunology Bacteriology Biological and medical sciences conjugate Enzyme-Linked Immunosorbent Assay Female Fundamental and applied biological sciences. Psychology Haemophilus influenzae Haemophilus Vaccines - immunology Haemophilus Vaccines - pharmacology Immunoglobulin G - biosynthesis Immunoglobulin G - blood Mice Mice, Inbred Strains Microbiology Neisseria meningitidis - immunology Polysaccharides, Bacterial - immunology porin Porins Rats Rats, Sprague-Dawley Recombinant Proteins - biosynthesis Recombinant Proteins - genetics Recombinant Proteins - immunology Tetanus Toxoid - pharmacology Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Conjugate - pharmacology |
| title | Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T02%3A48%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20studies%20on%20a%20recombinant%20group%20B%20meningococcal%20porin%20as%20a%20carrier%20for%20a%20novel%20Haemophilus%20influenzae%20type%20b%20conjugate%20vaccine&rft.jtitle=Vaccine&rft.au=Fusco,%20Peter%20C.&rft.date=1998-11-01&rft.volume=16&rft.issue=19&rft.spage=1842&rft.epage=1849&rft.pages=1842-1849&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(98)00174-1&rft_dat=%3Cproquest_cross%3E70008968%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70008968&rft_id=info:pmid/9795390&rft_els_id=S0264410X98001741&rfr_iscdi=true |